Samsung Biologics (207940.KS) reported second-quarter revenue of 1.3209 trillion won and operating profit of 586.4 billion won, the company said in a regulatory filing on the 23rd.
Revenue increased by 306.7 billion won, or 30.2%, from the same period a year earlier, while operating profit rose 109.2 billion won, or 22.9%.
Samsung Biologics said it sustained solid growth on the back of full operation of its Plants 1 through 4 and favorable exchange rate effects. Its operating profit margin remained in the 40% range, even as related costs were recognized in advance ahead of the full-scale revenue recognition from Plant 5 and its production facility in Rockville, in the United States.
